Journal of Clinical Oncology, Vol 19, Issue 7
(April), 2001: 1970-1975
© 2001 American Society for Clinical Oncology
Esophageal Cancer: The Mode of Lymphatic Tumor Cell Spread and Its Prognostic Significance
By Stefan B. Hosch,
Nikolas H. Stoecklein,
U. Pichlmeier,
Alexander Rehders,
Peter Scheunemann,
Axel Niendorf,
Wolfram T. Knoefel,
Jakob R. Izbicki
From the Department of Surgery, University of Hamburg; the Institute of Mathematics and Computer Science in Medicine, University Hospital Hamburg; and the Institute of Pathology, University Hospital Hamburg, Hamburg, Germany.
Address reprint requests to J.R. Izbicki, MD, PhD, Abt. für Allgemeinchirurgie, Universitätsklinikum Hamburg Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany; email: izbicki{at}uke .uni-hamburg.de.
PURPOSE: Data on skip metastases and their significance are lacking for esophageal cancer. This issue is important to determine the extent of lymphadenectomy for esophageal resection. In this study we examined the lymphatic spread in esophageal cancer by routine histopathology and by immunohistochemistry.
PATIENTS AND METHODS: A total of 1,584 resected lymph nodes were obtained from 86 patients with resected esophageal carcinoma and evaluated by routine histopathology. Additionally, frozen tissue sections of 540 lymph nodes classified as tumor-free by routine histopathology were screened for micrometastases by immunohistochemistry with the monoclonal antibody Ber-EP4. The lymph nodes were mapped according to the mapping scheme of the American Thoracic Society modified by Casson et al.
RESULTS: Forty-four patients (51%) had pN1 disease, and 61 patients (71%) harbored lymphatic micrometastases detected by immunohistochemistry. Skip metastases detected by routine histopathology were present in 34% of pN1 patients. Skipping of micrometastases detected by immunohistochemistry was found in 66%. The presence of micrometastases was associated with a significantly decreased relapse-free and overall survival (56.0 v 10.0 months and > 64 v 15 months, P < .0001 and P = .004, respectively). Cox regression analysis revealed the independent prognostic influence of micrometastases in lymph nodes. Lymph node skipping had no significant independent prognostic influence on survival.
CONCLUSION: Histopathologically and immunohistochemically detectable skip metastases are a frequent event in esophageal cancer. Only extensive lymph node sampling, in conjunction with immunohistochemical evaluation, will lead to accurate staging. An improved staging system is essential for more individualized adjuvant therapy.
This article has been cited by other articles:
|
|
|
|
 
M. J MacGuill, C. Barrett, N. Ravi, G. MacDonald, and J. V Reynolds
Isolated tumour cells in pathological node-negative lymph nodes adversely affect prognosis in cancer of the oesophagus or oesophagogastric junction
J. Clin. Pathol.,
October 1, 2007;
60(10):
1108 - 1111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Gervasoni Jr., S. Sbayi, and B. Cady
Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data.
Ann. Surg. Oncol.,
September 1, 2007;
14(9):
2443 - 2462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Prenzel, A. Konig, P. M. Schneider, C. Schnickmann, S. E. Baldus, W. Schroder, E. Bollschweiler, H. P. Dienes, R. P. Mueller, J. R. Izbicki, et al.
Reduced Incidence of Nodal Micrometastasis after Major Response to Neoadjuvant Chemoradiation in Locally Advanced Esophageal Cancer
Ann. Surg. Oncol.,
February 1, 2007;
14(2):
954 - 959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Rizk, E. Venkatraman, B. Park, R. Flores, M. S. Bains, and V. Rusch
The prognostic importance of the number of involved lymph nodes in esophageal cancer: Implications for revisions of the American Joint Committee on Cancer staging system
J. Thorac. Cardiovasc. Surg.,
December 1, 2006;
132(6):
1374 - 1381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Parungo, S. Ohnishi, S.-W. Kim, S. Kim, R. G. Laurence, E. G. Soltesz, F. Y. Chen, Y. L. Colson, L. H. Cohn, M. G. Bawendi, et al.
Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging
J. Thorac. Cardiovasc. Surg.,
April 1, 2005;
129(4):
844 - 850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Gollub, R. Lefkowitz, C. S. Moskowitz, D. Ilson, D. Kelsen, and H. Felderman
Pelvic CT in Patients with Esophageal Cancer
Am. J. Roentgenol.,
February 1, 2005;
184(2):
487 - 490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews
Multiple Management Modalities in Esophageal Cancer: Epidemiology, Presentation and Progression, Work-up, and Surgical Approaches
Oncologist,
April 1, 2004;
9(2):
137 - 146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ikeguchi, K.-i. Yamaguchi, and N. Kaibara
Clinical Significance of the Loss of KiSS-1 and Orphan G-Protein-Coupled Receptor (hOT7T175) Gene Expression in Esophageal Squamous Cell Carcinoma
Clin. Cancer Res.,
February 15, 2004;
10(4):
1379 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Machens, H.-J. Holzhausen, and H. Dralle
Skip Metastases in Thyroid Cancer Leaping the Central Lymph Node Compartment
Arch Surg,
January 1, 2004;
139(1):
43 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C. Enzinger and R. J. Mayer
Esophageal Cancer
N. Engl. J. Med.,
December 4, 2003;
349(23):
2241 - 2252.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ikeguchi, K. Fukuda, K.-i. Yamaguchi, A. Kondo, S.-i. Tsujitani, and N. Kaibara
Quantitative Analysis of Heparanase Gene Expression in Esophageal Squamous Cell Carcinoma
Ann. Surg. Oncol.,
April 1, 2003;
10(3):
297 - 304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S K Suvarna and T J Stephenson
A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy
J. Clin. Pathol.,
September 1, 2002;
55(9):
718 - 718.
[Full Text]
[PDF]
|
|
|
|
